PUBLISHER: Polaris Market Research | PRODUCT CODE: 1423974
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1423974
The global infectious disease diagnostic market size is expected to reach USD 42.39 Billion by 2032, according to a new study by Polaris Market Research. The report "Infectious Disease Diagnostic Market Share, Size, Trends, Industry Analysis Report, By Product; By Type of Testing (Laboratory Testing, PoC Testing); By Technology; By Disease Type; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The global market for infectious disease diagnostics is rapidly expanding due to technological advancements, the rising prevalence of infectious diseases, and growing awareness of the importance of early detection and treatment. The emergence of new diseases, combined with the threat of pandemics, has increased demand for rapid and accurate diagnostic tests. Technological advancements in molecular diagnostics, such as next-generation sequencing, PCR-based assays, and point-of-care testing, have significantly improved diagnostic test speed and accuracy, lowered costs, and increased accessibility.
Despite this, the expensive nature of advanced diagnostic tests is a major barrier to market growth, and as a result, their adoption is limited in resource-poor areas. Furthermore, increasing knowledge and access to medical care in developing countries reduces the need for infectious disease diagnostic tests.
Infectious diseases like COVID-19, influenza, and hepatitis continue to pose a significant threat to public health globally. The importance of accurate and timely diagnosis cannot be overstated since it is crucial in preventing further transmission and reducing the risk of outbreaks. To this end, prominent players in the market, such as Abbott Laboratories, bioMerieux, Roche Diagnostics, and Cepheid, are focusing on developing innovative diagnostic solutions that can detect a wide range of infectious diseases, including viral, bacterial, and fungal infections.
In 2023, the reagents, kits, and consumables generated the highest revenue share within the product segment. This is mainly attributable to the growing incidence of infectious diseases, resulting in a corresponding increase in demand for diagnostic tests. As a result, sales of reagents, kits, and consumables have surged, driving up their revenue share in the market.
In 2023, the laboratory testing segment held the major share of the market, and this was due to the critical role played by laboratory testing in identifying and tracking various infectious diseases.
The market has been significantly influenced by the pandemic, with COVID-19 being the dominating segment in disease type. This is attributed to the massive scale of the pandemic and the critical requirement for precise and prompt diagnosis of the virus.
In 2023, the North American region take the lead position, thanks to the strong healthcare infrastructure and advanced medical facilities in countries like the United States and Canada. These factors played a significant role in contributing to the region's market share.
The global key market players include Abbott, Becton Dickinson, bioMerieux, Bio-Rad Laboratories, Cepheid, Danaher, F. Hoffmann-La Roche Ltd, Hologic Inc., Luminex Corporation, Qiagen Inc., Thermo Fisher Scientific Inc., etc.
Polaris Market Research has segmented the infectious disease diagnostic market report based on product, type of testing, technology, disease type, end user, and region: